What are the effects of Mila
on children with Specific Learning Disorders?

What is Mila ?

A game for children with Specific Learning Disorders that aims to support learning through music and rhythm.

Mila results from 30 years of research on the impact of music on cognitive development

A groundbreaking clinical study

To demonstrate the scientific validity of its approach, Mila launched its first clinical study in the United States and Europe.

160 children involved
2 months of training
3000 hours of data for analysis

Built with our partners

Pitié-Salpêtrière (AP-HP)

The Pitié-Salpêtrière University Hospital is supporting us in the methodological design of the study and the recruitment of young patients.

Living & Learning Lab Neurodéveloppement

LiLLab plays a major role in the scientific support and design of the solution with the child users

Getting involved with Mila

Your child learns while having fun

Playing is an extraordinary and natural way to learn. Mila's multi-sensory approach to learning allows for beneficial motivational engagement through musical practice.

Benefit from a new tool

Using this playful approach to support and provide rehabilitation training has a securing dimension while enhancing the child’s ability to learn. Our work promotes accessibility and communication between families and medical teams

Get involved with a community

Participating in Mila’s research allows our product to evolve and be useful to the entire community of parents with children with specific learning disorders. Let’s collaborate and contribute together to the the tools we all need.

How does it work?

Once the recruitment is completed and your participation is validated, a tablet is given to you so that your child can start his or her Mila training.

9 weeks

of training

5 days

a week

25 minutes

games per day

Why 5 days a week?

Mila is designed above all as a moment of pleasure for the child and supports his learning in a playful way. Using it 5 days a week is a ritual: with small, short and regular sessions, allowing maximum benefits.

Why a touchscreen tablet?

Don't worry! (Very) far from us the idea to stick the child in front of a screen! As soon as the session is over (±25mn), the application pauses by itself: the child will only be able to come back the next day. Until then, it's better to go and play outside ;) The touchscreen tablet is only a means: a medium that allows us to create a rich and multimodal experience. This multisensoriality is a necessary condition to have a beneficial impact on the learning of children with learning disabilities. Finally, using a tablet is also a choice to develop technologies that will be accessible to all because of their low cost.

Stages of the study

1

Registration & Recruitment

Recruitment begins today. If you are interested in our study, simply fill out our form. We will contact you to determine if you are eligible. We will then be able to discuss the research conducted in person and agree on a two-hour meeting, which will allow us to do some tests together.

2

Training

Once included in the study, you will receive a tablet with the game. Mila will become a playful ritual for your child: they will practice daily, during the week, in short game sessions (±25mn).

3

End of the study & analysis

The training is over! A final meeting together to review the results through some tests and your feedback. The progress will then be analyzed anonymously and the analyses will be submitted to other researchers in the scientific community to critique the results.

Research team

Throughout the study you will be accompanied by and in contact with the Mila team.

Frequently Asked Questions

What is a clinical study?

This is a type of scientific study in which we evaluate the performance of a therapeutic device. A study is subject to a set of standards and constraints to ensure above all the safety of the patient. In our case, we are talking about a randomized study with a control arm, i.e. one group of children will be given Mila and the other group will be given a game that will act as a placebo.

Why is it important to control the placebo effect?

The placebo effect has been known since antiquity [1]: it is the positive effect that can be observed after any therapeutic act, independently of the effectiveness of the act itself. For example, to treat pain, the administration of a perfectly neutral substance such as sugar or water causes an improvement. This is not due to the effect of the substance itself, but to various non-specific psycho-physiological effects induced by the treatment. This effect has been widely observed in medicine, on subjective manifestations such as nausea or pain, but also on observable clinical and biological signs [3] (blood pressure, dopamine release in the brain, etc.). What we do know is that the placebo effect is attributable, at least in part, to the care situation itself, to the context. The placebo effect thus varies according to the relationship between the doctor and the patient, or according to the patient's expectations [6]. For example, the placebo effect is greater if the treatment is known to be expensive [7]. In any case, it is a very robust effect, observed not only in patients awaiting treatment but also in healthy volunteers with no particular problem [8].

Conclusion: even if a device has no efficacy of its own, it can have a positive effect on the person, simply because of the therapeutic situation that surrounds it. For this reason, if we wish to determine the efficacy of a device, it is essential to compare its effects with those produced by a device that is known to be neutral, but which is offered in the same situation as the treatment. This neutral treatment is called a placebo, and is referred to as a controlled trial, because the 'test' group is compared with a control group that receives the placebo.

[1] Patrick Lemoine, Le mystère du placebo (1996) aux éditions Odile Jacob

[2] De la Fuente-Fernández et al(2001). Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science, 293(5532), 1164-1166).

[3] Stone, D. A et al, (2005). Patient expectations in placebo‐controlled randomized clinical trials. Journal of evaluation in clinical practice, 11(1), 77-84.

[4] Espay, A. J. et al. (2015). Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology, 84(8), 794-802.

[5] Rosenzweig, P. et al. (1995). The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase I studies. British journal of clinical pharmacology, 39(6), 657-664.

What is the purpose of the study?

The main objective is to examine the effect of a musical training in the form of a video game, Mila, on the reading abilities of children with specific specific learning disorders.

How often should my child use Mila and for how long?

In order to obtain sufficient training time to observe an effect and a low risk of abandonment, the protocol will consist, for 9 weeks, of five training sessions per week of approximately 25 minutes each

Can I stop my participation during the clinical study?

Although the study is highly dependent on its completion by the participants, your safety will always come first and your wishes will obviously be respected if you were to discontinue your participation in the research.

Please note that the study protocol will be explained to you beforehand by a doctor and you will have a withdrawal period. A team will also be available at all times in case of technical problems or questions regarding the study.

Is there any follow-up after the study? For how long?

Yes, because clinical research is great, but especially if it contributes to improving the child's well-being on a daily basis! We will ask you again for 2 hours at the end of the school year (about 8 months later) to follow the evolutions

Do you have another question?

Don't hesitate to send us a message,

We will answer with pleasure

For now, our study is carried in France only

We respect your privacy.

As the data we process is very sensitive, we work with the CNIL (French Data Protection Authority) to ensure that we comply with the General Data Protection Regulation (GDPR). The data are protected within servers approved as Health Data Hosts (HDS).